diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/DM13296diaendo-13296Research ArticleОБЗОРЫREVIEWSСахарный диабет и псориатический артритDiabetes mellitus and psoriatic arthritishttps://orcid.org/0000-0002-5290-156XПаневинТ. С.PanevinT. S.

Паневин Тарас Сергеевич - к.м.н.

115522, Москва, Каширское шоссе, 34А

Taras S. Panevin - MD, PhD.

34A, Kashirskoe shosse, Moscow 115522

tarasel@list.ruhttps://orcid.org/0009-0002-0097-7236НеупокоеваА. А.NeupokoevaA. A.

Неупокоева Анастасия Андреевна – ординатор.

Москва

Anastasia A. Neupokoeva - MD, clinical resident.

Moscow

eroshenko.nastyusha@mail.ruhttps://orcid.org/0000-0003-0579-1131КоротаеваТ. В.KorotaevaT. V.

Коротаева Татьяна Викторовна - д.м.н.

Москва

Tatiana V. Korotaeva - MD, PhD.

Moscow

tatianakorotaeva@googlemail.comНаучно-исследовательский институт ревматологии им. В.А. Насоновой; Дальневосточный государственный медицинский университетРоссияV.A. Nasonova Research Institute of Rheumatology; The Far Eastern State Medical UniversityRussian FederationНаучно-исследовательский институт ревматологии им. В.А. НасоновойРоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation202524072025283240248Copyright © Паневин Т.С., Неупокоева А.А., Коротаева Т.В., 20252025Паневин Т.С., Неупокоева А.А., Коротаева Т.В.Panevin T.S., Neupokoeva A.A., Korotaeva T.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/13296

Псориатический артрит (ПсА) и псориаз (ПсО) часто ассоциируются с метаболическими нарушениями, включая ожирение, метаболический синдром, сахарный диабет (СД), и кардиоваскулярными заболеваниями (КВЗ). Считают, что ожирение, СД, ПсО и ПсА имеют сходные иммунопатогенетические механизмы. Хроническое воспаление тесно ассоциируется не только с развитием ПсО и ПсА, но и с формированием инсулинорезистентности и развитием СД. У больных СД, как и при ПсО и ПсА, повышены острофазовые показатели и провоспалительные цитокины, включая С-реактивный белок, фактор некроза опухоли α (ФНО-α), интерлейкины 1 и 6 (ИЛ-1 и ИЛ-6), которые независимо от наличия ожирения ассоциируются с развитием инсулинорезистентности. При ПсА и ПсО использование ингибиторов ФНО-α повышает чувствительность к инсулину и снижает инсулинорезистентность. Показано, что ингибитор ИЛ-12/23 устекинумаб замедляет развитие СД 1 типа у больных ПсО. Учитывая высокую распространенность СД при ПсА и ПсО, следует проводить скрининг для выявления заболевания. При выборе терапии пациентам с ПсА, ПсО в сочетании с СД 2 типа следует учитывать возможность некоторых лекарственных препаратов улучшать состояние углеводного обмена, а также использовать при необходимости сахароснижающие препараты.

Psoriatic arthritis (PsA) and psoriasis (PsO) are often associated with metabolic disorders including obesity, metabolic syndrome, diabetes mellitus (DM) and cardiovascular diseases (CVD). It is believed that obesity, DM, PsO and PsA have similar immunopathogenetic mechanisms. Chronic inflammation is closely associated not only with the development of PsO and PsA, but also with the formation of insulin resistance and the development of DM. In patients with DM, as well as with PsO and PsA, acute phase indices and proinflammatory cytokines are increased, including C-reactive protein, tumor necrosis factor α (TNF-α), interleukins 1 and 6 (IL-1 and IL-6), which, regardless of the presence of obesity, are associated with the development of insulin resistance. In PsA and PsO, the use of TNF-α inhibitors increases insulin sensitivity and reduces insulin resistance. It has been shown that the IL-12/23 inhibitor Ustekinumab slows down the development of type 1 diabetes in patients with PsO. Given the high prevalence of diabetes in PsA and PsO, screening should be performed to detect the disease. When choosing therapy for patients with PsA, PsO in combination with type 2 diabetes, the ability of some drugs to improve carbohydrate metabolism should be taken into account, as well as the use of hypoglycemic drugs if necessary.

сахарный диабетожирениепсориазпсориатический артритустекинумабdiabetes mellitusobesitypsoriasispsoriatic arthritisustekinumabРабота выполнена в рамках фундаментальной научной тематики ФГБНУ НИИР им. В.А. Насоновой № 125020501435-8 «Эволюция аксиальных спондилоартритов на основе комплексного динамического изучения молекулярно-биологических, молекулярно-генетических, клинико-визуализационных факторов прогрессирования заболевания, качества жизни, коморбидности и таргетной инновационной терапии».ReferencesRitchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376(10):957-70. doi: https://doi.org/10.1056/NEJMra1505557Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376(10):957-70. doi: https://doi.org/10.1056/NEJMra1505557Merola JF, Tian H, Patil D, Richardson C, Scott A, Chen YH, et al. Incidence and prevalence of psoriatic arthritis in patients with psoriasis stratified by psoriasis disease severity: Retrospective analysis of an electronic health records database in the United States. J Am Acad Dermatol. 2022;86(4):748-757. doi: https://doi.org/10.1016/j.jaad.2021.09.019Merola JF, Tian H, Patil D, Richardson C, Scott A, Chen YH, et al. Incidence and prevalence of psoriatic arthritis in patients with psoriasis stratified by psoriasis disease severity: Retrospective analysis of an electronic health records database in the United States. J Am Acad Dermatol. 2022;86(4):748-757. doi: https://doi.org/10.1016/j.jaad.2021.09.019Stirnimann M, Maul JT, Vallejo-Yagüe E, Burden AM, Moeller B, Nissen MJ, et al. OP0064 Obesity in psoriatic arthritis is increasingly affecting men and appears less dependent of socioeconomic status than in the general population. Ann Rheum Dis. 2023;82:44. doi: https://doi.org/10.1136/annrheumdis-2023-eular.3678Stirnimann M, Maul JT, Vallejo-Yagüe E, Burden AM, Moeller B, Nissen MJ, et al. OP0064 Obesity in psoriatic arthritis is increasingly affecting men and appears less dependent of socioeconomic status than in the general population. Ann Rheum Dis. 2023;82:44. doi: https://doi.org/10.1136/annrheumdis-2023-eular.3678Chandrasekaran P, Weiskirchen R. The Role of Obesity in Type 2 Diabetes Mellitus-An Overview. Int J Mol Sci. 2024;25(3):1882. doi: https://doi.org/10.3390/ijms25031882Chandrasekaran P, Weiskirchen R. The Role of Obesity in Type 2 Diabetes Mellitus-An Overview. Int J Mol Sci. 2024;25(3):1882. doi: https://doi.org/10.3390/ijms25031882Корсакова Ю.Л., Коротаева Т.В., Логинова Е.Ю., и др. Клиникоинструментальная характеристика псориатического артрита у мужчин и женщин. Данные когортного наблюдательного исследования // Терапевтический архив. — 2024. — Т. 96. — №5. — С. 479-485. doi: https://doi.org/10.26442/00403660.2024.05.202703Korsakova YL, Korotaeva TV, Loginova EI, et al. Clinical and instrumental characteristics of psoriatic arthritis in men and women. Data from a cohort observational study. Terapevticheskii arkhiv. 2024;96(5):479-485 (In Russ.). doi: https://doi.org/10.26442/00403660.2024.05.202703Корсакова Ю.Л., Коротаева Т.В., Логинова Е.Ю., Губарь Е.Е., Василенко Е.А., и др. Взаимосвязь ожирения, кардиометаболических нарушений и активности заболевания у больных псориатическим артритом: данные Общероссийского регистра // Терапевтический архив. — 2021. — Т. 93. — № 5. — С. 573–580 doi: https://doi.org/10.26442/00403660.2021.05.200Korsakova YuL, Korotaeva TV, Loginova EIu, Gubar EE, Vasilenko EA, et al. The relationship between obesity, cardiometabolic disorders and disease activityin psoriatic arthritis patients: data from the Russian register. Terapevticheskii Arkhiv. 2021; 93 (5): 573–580 (In Russ.) doi: https://doi.org/10.26442/00403660.2021.05.200Dal Bello G, Gisondi P, Idolazzi L, Girolomoni G. Psoriatic Arthritis and Diabetes Mellitus: A Narrative Review. Rheumatol Ther. 2020;7(2):271-285. doi: https://doi.org/10.1007/s40744-020-00206-7Dal Bello G, Gisondi P, Idolazzi L, Girolomoni G. Psoriatic Arthritis and Diabetes Mellitus: A Narrative Review. Rheumatol Ther. 2020;7(2):271-285. doi: https://doi.org/10.1007/s40744-020-00206-7Coto-Segura P, Eiris-Salvado N, González-Lara L, et al. Psoriasis, psoriatic arthritis and type 2 diabetes mellitus: a systematic review and meta-analysis. Br J Dermatol. 2013;169(4):783-793. doi: https://doi.org/10.1111/bjd.12473Coto-Segura P, Eiris-Salvado N, González-Lara L, et al. Psoriasis, psoriatic arthritis and type 2 diabetes mellitus: a systematic review and meta-analysis. Br J Dermatol. 2013;169(4):783-793. doi: https://doi.org/10.1111/bjd.12473Eder L, Chandran V, Cook R, Gladman DD. The Risk of Developing Diabetes Mellitus in Patients with Psoriatic Arthritis: A Cohort Study. J Rheumatol. 2017;44(3):286-291. doi: https://doi.org/10.3899/jrheum.160861Eder L, Chandran V, Cook R, Gladman DD. The Risk of Developing Diabetes Mellitus in Patients with Psoriatic Arthritis: A Cohort Study. J Rheumatol. 2017;44(3):286-291. doi: https://doi.org/10.3899/jrheum.160861Mok CC, Ko GT, Ho LY, Yu KL, Chan PT, To CH. Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis. Arthritis Care Res (Hoboken). 2011;63(2):195-202. doi: https://doi.org/10.1002/acr.20363Mok CC, Ko GT, Ho LY, Yu KL, Chan PT, To CH. Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis. Arthritis Care Res (Hoboken). 2011;63(2):195-202. doi: https://doi.org/10.1002/acr.20363Dubreuil M, Rho YH, Man A, et al. Diabetes incidence in psoriatic arthritis, psoriasis and rheumatoid arthritis: a UK population-based cohort study. Rheumatology (Oxford). 2014;53(2):346-352. doi: https://doi.org/10.1093/rheumatology/ket343Dubreuil M, Rho YH, Man A, et al. Diabetes incidence in psoriatic arthritis, psoriasis and rheumatoid arthritis: a UK population-based cohort study. Rheumatology (Oxford). 2014;53(2):346-352. doi: https://doi.org/10.1093/rheumatology/ket343Shah K, Paris M, Mellars L, Changolkar A, Mease PJ. Real-world burden of comorbidities in US patients with psoriatic arthritis. RMD Open. 2017;3(2):e000588. doi: https://doi.org/10.1136/rmdopen-2017-000588Shah K, Paris M, Mellars L, Changolkar A, Mease PJ. Real-world burden of comorbidities in US patients with psoriatic arthritis. RMD Open. 2017;3(2):e000588. doi: https://doi.org/10.1136/rmdopen-2017-000588Dreiher J, Freud T, Cohen AD. Psoriatic arthritis and diabetes: a population-based cross-sectional study. Dermatol Res Pract. 2013;2013:580404. doi: https://doi.org/10.1155/2013/580404Dreiher J, Freud T, Cohen AD. Psoriatic arthritis and diabetes: a population-based cross-sectional study. Dermatol Res Pract. 2013;2013:580404. doi: https://doi.org/10.1155/2013/580404Bhole VM, Choi HK, Burns LC, et al. Differences in body mass index among individuals with PsA, psoriasis, RA and the general population. Rheumatology (Oxford). 2012;51(3):552-556. doi: https://doi.org/10.1093/rheumatology/ker349Bhole VM, Choi HK, Burns LC, et al. Differences in body mass index among individuals with PsA, psoriasis, RA and the general population. Rheumatology (Oxford). 2012;51(3):552-556. doi: https://doi.org/10.1093/rheumatology/ker349Queiro R, Lorenzo A, Pardo E, Brandy A, Coto P, Ballina J. Prevalence and type II diabetes-associated factors in psoriatic arthritis. Clin Rheumatol. 2018;37(4):1059-1064. doi: https://doi.org/10.1007/s10067-018-4042-1Queiro R, Lorenzo A, Pardo E, Brandy A, Coto P, Ballina J. Prevalence and type II diabetes-associated factors in psoriatic arthritis. Clin Rheumatol. 2018;37(4):1059-1064. doi: https://doi.org/10.1007/s10067-018-4042-1Дедов И.И., Шестакова М.В., Викулова О.К., и соавт. Сахарный диабет в Российской Федерации: динамика эпидемиологических показателей по данным Федерального регистра сахарного диабета за период 2010–2022 гг. // Сахарный диабет. 2023. — Т.26. — №2. — С.104-123 doi: https://doi.org/10.14341/DM13035Dedov II, Shestakova MV, Vikulova OK, et al. Diabetes mellitus in the Russian Federation: dynamics of epidemiological indicators according to the Federal Register of Diabetes Mellitus for the period 2010–2022. Diabetes Mellitus. 2023;26(2):104-123 (In Russ.) doi: https://doi.org/10.14341/DM13035Калмыкова З.А., Кононенко И.В., Смирнова О.М., Шестакова М.В. Сигнальные пути гибели β-клеток при сахарном диабете 2 типа: роль врожденного иммунитета // Сахарный диабет. — 2020. — Т. 23. — №2. — С. 174-184 doi: https://doi.org/10.14341/DM10242Kalmykova ZA, Kononenko IV, Smirnova OM, Shestakova MV. Signaling pathways of β-cell death in type 2 diabetes mellitus: the role of innate immunity. Diabetes Mellitus. 2020;23(2):174-184 (In Russ.) doi: https://doi.org/10.14341/DM10242Scala E, Mercurio L, Albanesi C, Madonna S. The Intersection of the Pathogenic Processes Underlying Psoriasis and the Comorbid Condition of Obesity. Life (Basel). 2024;14(6):733. doi: https://doi.org/10.3390/life14060733Scala E, Mercurio L, Albanesi C, Madonna S. The Intersection of the Pathogenic Processes Underlying Psoriasis and the Comorbid Condition of Obesity. Life (Basel). 2024;14(6):733. doi: https://doi.org/10.3390/life14060733Al-Hashemi WKH, Taha GI, Aldhaher ZA, Mutlak SS. Interleukin 23 and HSV in diabetic and non-diabetic obese females. Biochemical & Cellular Archives. 2022;22(1):721-725Al-Hashemi WKH, Taha GI, Aldhaher ZA, Mutlak SS. Interleukin 23 and HSV in diabetic and non-diabetic obese females. Biochemical & Cellular Archives. 2022;22(1):721-725Abdel-Moneim A, Bakery HH, Allam G. The potential pathogenic role of IL-17/Th17 cells in both type 1 and type 2 diabetes mellitus. Biomed Pharmacother. 2018;101:287-292. doi: https://doi.org/10.1016/j.biopha.2018.02.103Abdel-Moneim A, Bakery HH, Allam G. The potential pathogenic role of IL-17/Th17 cells in both type 1 and type 2 diabetes mellitus. Biomed Pharmacother. 2018;101:287-292. doi: https://doi.org/10.1016/j.biopha.2018.02.103Cohen AD, Dreiher J, Shapiro Y, et al. Psoriasis and diabetes: a population-based cross-sectional study. J Eur Acad Dermatol Venereol. 2008;22(5):585-589. doi: https://doi.org/10.1111/j.1468-3083.2008.02636.xCohen AD, Dreiher J, Shapiro Y, et al. Psoriasis and diabetes: a population-based cross-sectional study. J Eur Acad Dermatol Venereol. 2008;22(5):585-589. doi: https://doi.org/10.1111/j.1468-3083.2008.02636.xWolk K, Sabat R. Adipokines in psoriasis: An important link between skin inflammation and metabolic alterations. Rev Endocr Metab Disord. 2016;17(3):305-317. doi: https://doi.org/10.1007/s11154-016-9381-0Wolk K, Sabat R. Adipokines in psoriasis: An important link between skin inflammation and metabolic alterations. Rev Endocr Metab Disord. 2016;17(3):305-317. doi: https://doi.org/10.1007/s11154-016-9381-0Shibata S, Saeki H, Tada Y, Karakawa M, Komine M, Tamaki K. Serum high molecular weight adiponectin levels are decreased in psoriasis patients. J Dermatol Sci. 2009;55(1):62-63. doi: https://doi.org/10.1016/j.jdermsci.2009.02.009Shibata S, Saeki H, Tada Y, Karakawa M, Komine M, Tamaki K. Serum high molecular weight adiponectin levels are decreased in psoriasis patients. J Dermatol Sci. 2009;55(1):62-63. doi: https://doi.org/10.1016/j.jdermsci.2009.02.009Shibata S, Tada Y, Hau C, et al. Adiponectin as an anti-inflammatory factor in the pathogenesis of psoriasis: induction of elevated serum adiponectin levels following therapy. Br J Dermatol. 2011;164(3):667-670. doi: https://doi.org/10.1111/j.1365-2133.2010.10123.xShibata S, Tada Y, Hau C, et al. Adiponectin as an anti-inflammatory factor in the pathogenesis of psoriasis: induction of elevated serum adiponectin levels following therapy. Br J Dermatol. 2011;164(3):667-670. doi: https://doi.org/10.1111/j.1365-2133.2010.10123.xWhite MF, Kahn CR. The insulin signaling system. J Biol Chem. 1994;269(1):1-4White MF, Kahn CR. The insulin signaling system. J Biol Chem. 1994;269(1):1-4Kanety H, Feinstein R, Papa MZ, Hemi R, Karasik A. Tumor necrosis factor alpha-induced phosphorylation of insulin receptor substrate-1 (IRS-1). Possible mechanism for suppression of insulin-stimulated tyrosine phosphorylation of IRS-1. J Biol Chem. 1995;270(40):23780-23784. doi: https://doi.org/10.1074/jbc.270.40.23780Kanety H, Feinstein R, Papa MZ, Hemi R, Karasik A. Tumor necrosis factor alpha-induced phosphorylation of insulin receptor substrate-1 (IRS-1). Possible mechanism for suppression of insulin-stimulated tyrosine phosphorylation of IRS-1. J Biol Chem. 1995;270(40):23780-23784. doi: https://doi.org/10.1074/jbc.270.40.23780Aguirre V, Werner ED, Giraud J, Lee YH, Shoelson SE, White MF. Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action. J Biol Chem. 2002;277(2):1531-1537. doi: https://doi.org/10.1074/jbc.M101521200Aguirre V, Werner ED, Giraud J, Lee YH, Shoelson SE, White MF. Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action. J Biol Chem. 2002;277(2):1531-1537. doi: https://doi.org/10.1074/jbc.M101521200Nanus DE, Filer AD, Hughes B, et al. TNFα regulates cortisol metabolism in vivo in patients with inflammatory arthritis. Ann Rheum Dis. 2015;74(2):464-469. doi: https://doi.org/10.1136/annrheumdis-2013-203926Nanus DE, Filer AD, Hughes B, et al. TNFα regulates cortisol metabolism in vivo in patients with inflammatory arthritis. Ann Rheum Dis. 2015;74(2):464-469. doi: https://doi.org/10.1136/annrheumdis-2013-203926Coates LC, Soriano ER, Corp N, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021 [published correction appears in Nat Rev Rheumatol. 2022;18(12):734. doi: 10.1038/s41584-022-00861-w]. Nat Rev Rheumatol. 2022;18(8):465-479. doi: https://doi.org/10.1038/s41584-022-00798-0Coates LC, Soriano ER, Corp N, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021 [published correction appears in Nat Rev Rheumatol. 2022;18(12):734. doi: 10.1038/s41584-022-00861-w]. Nat Rev Rheumatol. 2022;18(8):465-479. doi: https://doi.org/10.1038/s41584-022-00798-0Aimo C, Cosentino VL, Sequeira G, Kerzberg E. Use of systemic glucocorticoids in patients with psoriatic arthritis by Argentinian and other Latin-American rheumatologists. Rheumatol Int. 2019;39(4):723-727. doi: https://doi.org/10.1007/s00296-019-04266-zAimo C, Cosentino VL, Sequeira G, Kerzberg E. Use of systemic glucocorticoids in patients with psoriatic arthritis by Argentinian and other Latin-American rheumatologists. Rheumatol Int. 2019;39(4):723-727. doi: https://doi.org/10.1007/s00296-019-04266-zHwang JL, Weiss RE. Steroid-induced diabetes: a clinical and molecular approach to understanding and treatment. Diabetes Metab Res Rev. 2014;30(2):96-102. doi: https://doi.org/10.1002/dmrr.2486Hwang JL, Weiss RE. Steroid-induced diabetes: a clinical and molecular approach to understanding and treatment. Diabetes Metab Res Rev. 2014;30(2):96-102. doi: https://doi.org/10.1002/dmrr.2486Katsuyama T, Sada KE, Namba S, et al. Risk factors for the development of glucocorticoid-induced diabetes mellitus. Diabetes Res Clin Pract. 2015;108(2):273-279. doi: https://doi.org/10.1016/j.diabres.2015.02.010Katsuyama T, Sada KE, Namba S, et al. Risk factors for the development of glucocorticoid-induced diabetes mellitus. Diabetes Res Clin Pract. 2015;108(2):273-279. doi: https://doi.org/10.1016/j.diabres.2015.02.010Szeto CC, Sugano K, Wang JG, et al. Non-steroidal anti-inflammatory drug (NSAID) therapy in patients with hypertension, cardiovascular, renal or gastrointestinal comorbidities: joint APAGE/APLAR/APSDE/ APSH/APSN/PoA recommendations. Gut. 2020;69(4):617-629. doi: https://doi.org/10.1136/gutjnl-2019-319300Szeto CC, Sugano K, Wang JG, et al. Non-steroidal anti-inflammatory drug (NSAID) therapy in patients with hypertension, cardiovascular, renal or gastrointestinal comorbidities: joint APAGE/APLAR/APSDE/ APSH/APSN/PoA recommendations. Gut. 2020;69(4):617-629. doi: https://doi.org/10.1136/gutjnl-2019-319300Dehpouri T, Rokni GR, Narenjbon NA, et al. Evaluation of the glycemic effect of methotrexate in psoriatic arthritis patients with metabolic syndrome: A pilot study. Dermatol Reports. 2019;11(1):7965. doi: https://doi.org/10.4081/dr.2019.7965Dehpouri T, Rokni GR, Narenjbon NA, et al. Evaluation of the glycemic effect of methotrexate in psoriatic arthritis patients with metabolic syndrome: A pilot study. Dermatol Reports. 2019;11(1):7965. doi: https://doi.org/10.4081/dr.2019.7965Chen HH, Chen DY, Lin CC, et al. Association between use of disease-modifying antirheumatic drugs and diabetes in patients with ankylosing spondylitis, rheumatoid arthritis, or psoriasis/ psoriatic arthritis: a nationwide, population-based cohort study of 84,989 patients. Ther Clin Risk Manag. 2017;13:583-592. doi: https://doi.org/10.2147/TCRM.S130666Chen HH, Chen DY, Lin CC, et al. Association between use of disease-modifying antirheumatic drugs and diabetes in patients with ankylosing spondylitis, rheumatoid arthritis, or psoriasis/ psoriatic arthritis: a nationwide, population-based cohort study of 84,989 patients. Ther Clin Risk Manag. 2017;13:583-592. doi: https://doi.org/10.2147/TCRM.S130666Chen J, Sun J, Doscas ME, et al. Control of hyperglycemia in male mice by leflunomide: mechanisms of action. J Endocrinol. 2018;237(1):43-58. doi: https://doi.org/10.1530/JOE-17-0536Chen J, Sun J, Doscas ME, et al. Control of hyperglycemia in male mice by leflunomide: mechanisms of action. J Endocrinol. 2018;237(1):43-58. doi: https://doi.org/10.1530/JOE-17-0536Haas RM, Li P, Chu JW. Glucose-lowering effects of sulfasalazine in type 2 diabetes. Diabetes Care. 2005;28(9):2238-2239. doi: https://doi.org/10.2337/diacare.28.9.2238Haas RM, Li P, Chu JW. Glucose-lowering effects of sulfasalazine in type 2 diabetes. Diabetes Care. 2005;28(9):2238-2239. doi: https://doi.org/10.2337/diacare.28.9.2238da Silva BS, Bonfá E, de Moraes JC, et al. Effects of anti-TNF therapy on glucose metabolism in patients with ankylosing spondylitis, psoriatic arthritis or juvenile idiopathic arthritis. Biologicals. 2010;38(5):567-569. doi: https://doi.org/10.1016/j.biologicals.2010.05.003da Silva BS, Bonfá E, de Moraes JC, et al. Effects of anti-TNF therapy on glucose metabolism in patients with ankylosing spondylitis, psoriatic arthritis or juvenile idiopathic arthritis. Biologicals. 2010;38(5):567-569. doi: https://doi.org/10.1016/j.biologicals.2010.05.003Solomon DH, Massarotti E, Garg R, Liu J, Canning C, Schneeweiss S. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA. 2011;305(24):2525-2531. doi: https://doi.org/10.1001/jama.2011.878Solomon DH, Massarotti E, Garg R, Liu J, Canning C, Schneeweiss S. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA. 2011;305(24):2525-2531. doi: https://doi.org/10.1001/jama.2011.878Egeberg A, Wu JJ, Korman N, et al. Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: Results from UNCOVER-1, UNCOVER-2, and UNCOVER-3. J Am Acad Dermatol. 2018;79(1):104-109.e8. doi: https://doi.org/10.1016/j.jaad.2018.02.074Egeberg A, Wu JJ, Korman N, et al. Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: Results from UNCOVER-1, UNCOVER-2, and UNCOVER-3. J Am Acad Dermatol. 2018;79(1):104-109.e8. doi: https://doi.org/10.1016/j.jaad.2018.02.074Gerdes S, Pinter A, Papavassilis C, Reinhardt M. Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients. J Eur Acad Dermatol Venereol. 2020;34(3):533-541. doi: https://doi.org/10.1111/jdv.16004Gerdes S, Pinter A, Papavassilis C, Reinhardt M. Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients. J Eur Acad Dermatol Venereol. 2020;34(3):533-541. doi: https://doi.org/10.1111/jdv.16004Hasnain SZ, Borg DJ, Harcourt BE, et al. Glycemic control in diabetes is restored by therapeutic manipulation of cytokines that regulate beta cell stress. Nat Med. 2014;20(12):1417-1426. doi: https://doi.org/10.1038/nm.3705Hasnain SZ, Borg DJ, Harcourt BE, et al. Glycemic control in diabetes is restored by therapeutic manipulation of cytokines that regulate beta cell stress. Nat Med. 2014;20(12):1417-1426. doi: https://doi.org/10.1038/nm.3705Vaiopoulos AG, Dalamaga M, Katsimbri P, et al. Real-world data show high efficacy of IL23 inhibitors guselkumab and risankizumab in psoriatic arthritis and difficult-to-treat areas. Int J Dermatol. 2023;62(11):1404-1413. doi: https://doi.org/10.1111/ijd.16849Vaiopoulos AG, Dalamaga M, Katsimbri P, et al. Real-world data show high efficacy of IL23 inhibitors guselkumab and risankizumab in psoriatic arthritis and difficult-to-treat areas. Int J Dermatol. 2023;62(11):1404-1413. doi: https://doi.org/10.1111/ijd.16849Pyne NJ, Furman BL. Cyclic nucleotide phosphodiesterases in pancreatic islets. Diabetologia. 2003;46(9):1179-1189. doi: https://doi.org/10.1007/s00125-003-1176-7Pyne NJ, Furman BL. Cyclic nucleotide phosphodiesterases in pancreatic islets. Diabetologia. 2003;46(9):1179-1189. doi: https://doi.org/10.1007/s00125-003-1176-7Dattola A, Del Duca E, Saraceno R, Gramiccia T, Bianchi L. Safety evaluation of apremilast for the treatment of psoriasis. Expert Opin Drug Saf. 2017;16(3):381-385. doi: https://doi.org/10.1080/14740338.2017.1288714Dattola A, Del Duca E, Saraceno R, Gramiccia T, Bianchi L. Safety evaluation of apremilast for the treatment of psoriasis. Expert Opin Drug Saf. 2017;16(3):381-385. doi: https://doi.org/10.1080/14740338.2017.1288714Puig L, Korman N, Greggio C, Cirulli J, Teng L, Chandran V, et al. Long-term hemoglobin A1c changes with apremilast in patients with psoriasis and psoriatic arthritis: pooled analysis of phase 3 ESTEEM and PALACE trials and phase 3b LIBERATE trial. J Am Acad Dermatol. 2019;81:89. doi: https://doi.org/10.1016/j.jaad.2019.06.346Puig L, Korman N, Greggio C, Cirulli J, Teng L, Chandran V, et al. Long-term hemoglobin A1c changes with apremilast in patients with psoriasis and psoriatic arthritis: pooled analysis of phase 3 ESTEEM and PALACE trials and phase 3b LIBERATE trial. J Am Acad Dermatol. 2019;81:89. doi: https://doi.org/10.1016/j.jaad.2019.06.346Ritchlin CT, Giles JT, Ogdie A, et al. Tofacitinib in Patients With Psoriatic Arthritis and Metabolic Syndrome: A Post hoc Analysis of Phase 3 Studies. ACR Open Rheumatol. 2020;2(10):543-554. doi: https://doi.org/10.1002/acr2.11166Ritchlin CT, Giles JT, Ogdie A, et al. Tofacitinib in Patients With Psoriatic Arthritis and Metabolic Syndrome: A Post hoc Analysis of Phase 3 Studies. ACR Open Rheumatol. 2020;2(10):543-554. doi: https://doi.org/10.1002/acr2.11166Di Muzio C, Di Cola I, Shariat Panahi A, et al. The effects of suppressing inflammation by tofacitinib may simultaneously improve glycaemic parameters and inflammatory markers in rheumatoid arthritis patients with comorbid type 2 diabetes: a proof-of-concept, open, prospective, clinical study. Arthritis Res Ther. 2024;26(1):14. doi: https://doi.org/10.1186/s13075-023-03249-7Di Muzio C, Di Cola I, Shariat Panahi A, et al. The effects of suppressing inflammation by tofacitinib may simultaneously improve glycaemic parameters and inflammatory markers in rheumatoid arthritis patients with comorbid type 2 diabetes: a proof-of-concept, open, prospective, clinical study. Arthritis Res Ther. 2024;26(1):14. doi: https://doi.org/10.1186/s13075-023-03249-7Jia Y, Lao Y, Zhu H, Li N, Leung SW. Is metformin still the most efficacious first-line oral hypoglycaemic drug in treating type 2 diabetes? A network meta-analysis of randomized controlled trials. Obes Rev. 2019;20(1):1-12. doi: https://doi.org/10.1111/obr.12753Jia Y, Lao Y, Zhu H, Li N, Leung SW. Is metformin still the most efficacious first-line oral hypoglycaemic drug in treating type 2 diabetes? A network meta-analysis of randomized controlled trials. Obes Rev. 2019;20(1):1-12. doi: https://doi.org/10.1111/obr.12753Елисеев М.С., Паневин Т.С., Желябина О.В., Насонов Е.Л. Перспективы применения метформина у пациентов с нарушением уратного обмена // Терапевтический архив. — 2021. — Т. 93. — №5. — С. 628-634. doi: https://doi.org/10.26442/00403660.2021.05.200795Елисеев М.С., Паневин Т.С., Желябина О.В., Насонов Е.Л. Перспективы применения метформина у пациентов с нарушением уратного обмена // Терапевтический архив. — 2021. — Т. 93. — №5. — С. 628-634. [Eliseev MS, Panevin TS, Zhelyabina OV, Nasonov EL. Advantages of the use of metformin in patients with impaired uric acid metabolism. Terapevticheskii arkhiv. 2021;93(5):628-634 (In Russ.)]. doi: https://doi.org/10.26442/00403660.2021.05.200795Mangoni AA, Sotgia S, Zinellu A, et al. Methotrexate and cardiovascular prevention: an appraisal of the current evidence. Ther Adv Cardiovasc Dis. 2023;17:17539447231215213. doi: https://doi.org/10.1177/17539447231215213Mangoni AA, Sotgia S, Zinellu A, et al. Methotrexate and cardiovascular prevention: an appraisal of the current evidence. Ther Adv Cardiovasc Dis. 2023;17:17539447231215213. doi: https://doi.org/10.1177/17539447231215213Liu Y, Yang F, Ma W, Sun Q. Metformin inhibits proliferation and proinflammatory cytokines of human keratinocytes in vitro via mTOR-signaling pathway. Pharm Biol. 2016;54(7):1173-1178. doi: https://doi.org/10.3109/13880209.2015.1057652Liu Y, Yang F, Ma W, Sun Q. Metformin inhibits proliferation and proinflammatory cytokines of human keratinocytes in vitro via mTOR-signaling pathway. Pharm Biol. 2016;54(7):1173-1178. doi: https://doi.org/10.3109/13880209.2015.1057652Li W, Ma W, Zhong H, Liu W, Sun Q. Metformin inhibits proliferation of human keratinocytes through a mechanism associated with activation of the MAPK signaling pathway. Exp Ther Med. 2014;7(2):389-392. doi: https://doi.org/10.3892/etm.2013.1416Li W, Ma W, Zhong H, Liu W, Sun Q. Metformin inhibits proliferation of human keratinocytes through a mechanism associated with activation of the MAPK signaling pathway. Exp Ther Med. 2014;7(2):389-392. doi: https://doi.org/10.3892/etm.2013.1416Singh S, Bhansali A. Randomized placebo control study of insulin sensitizers (Metformin and Pioglitazone) in psoriasis patients with metabolic syndrome (Topical Treatment Cohort). BMC Dermatol. 2016;16(1):12. doi: https://doi.org/10.1186/s12895-016-0049-ySingh S, Bhansali A. Randomized placebo control study of insulin sensitizers (Metformin and Pioglitazone) in psoriasis patients with metabolic syndrome (Topical Treatment Cohort). BMC Dermatol. 2016;16(1):12. doi: https://doi.org/10.1186/s12895-016-0049-ySingh S, Bhansali A. Randomized Placebo Control Study of Metformin in Psoriasis Patients with Metabolic Syndrome (Systemic Treatment Cohort). Indian J Endocrinol Metab. 2017;21(4):581-587. doi: https://doi.org/10.4103/ijem.IJEM_46_17Singh S, Bhansali A. Randomized Placebo Control Study of Metformin in Psoriasis Patients with Metabolic Syndrome (Systemic Treatment Cohort). Indian J Endocrinol Metab. 2017;21(4):581-587. doi: https://doi.org/10.4103/ijem.IJEM_46_17Tam HTX, Thuy LND, Vinh NM, Anh TN, Van BT. The Combined Use of Metformin and Methotrexate in Psoriasis Patients with Metabolic Syndrome. Dermatol Res Pract. 2022;2022:9838867. doi: https://doi.org/10.1155/2022/9838867Tam HTX, Thuy LND, Vinh NM, Anh TN, Van BT. The Combined Use of Metformin and Methotrexate in Psoriasis Patients with Metabolic Syndrome. Dermatol Res Pract. 2022;2022:9838867. doi: https://doi.org/10.1155/2022/9838867Su YJ, Chen TH, Hsu CY, Chiu WT, Lin YS, Chi CC. Safety of Metformin in Psoriasis Patients With Diabetes Mellitus: A 17-Year Population-Based Real-World Cohort Study. J Clin Endocrinol Metab. 2019;104(8):3279-3286. doi: https://doi.org/10.1210/jc.2018-02526Su YJ, Chen TH, Hsu CY, Chiu WT, Lin YS, Chi CC. Safety of Metformin in Psoriasis Patients With Diabetes Mellitus: A 17-Year Population-Based Real-World Cohort Study. J Clin Endocrinol Metab. 2019;104(8):3279-3286. doi: https://doi.org/10.1210/jc.2018-02526Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature. 1998;391(6662):79-82. doi: https://doi.org/10.1038/34178Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature. 1998;391(6662):79-82. doi: https://doi.org/10.1038/34178Ellis CN, Varani J, Fisher GJ, et al. Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation. Arch Dermatol. 2000;136(5):609-616. doi: https://doi.org/10.1001/archderm.136.5.609Ellis CN, Varani J, Fisher GJ, et al. Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation. Arch Dermatol. 2000;136(5):609-616. doi: https://doi.org/10.1001/archderm.136.5.609Malhotra A, Shafiq N, Rajagopalan S, Dogra S, Malhotra S. Thiazolidinediones for plaque psoriasis: a systematic review and meta-analysis. Evid Based Med. 2012;17(6):171-176. doi: https://doi.org/10.1136/ebmed-2011-100388Malhotra A, Shafiq N, Rajagopalan S, Dogra S, Malhotra S. Thiazolidinediones for plaque psoriasis: a systematic review and meta-analysis. Evid Based Med. 2012;17(6):171-176. doi: https://doi.org/10.1136/ebmed-2011-100388Chang G, Wang J, Song J, Zhang Z, Zhang L. Efficacy and safety of pioglitazone for treatment of plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials. J Dermatolog Treat. 2020;31(7):680-686. doi: https://doi.org/10.1080/09546634.2019.1610552Chang G, Wang J, Song J, Zhang Z, Zhang L. Efficacy and safety of pioglitazone for treatment of plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials. J Dermatolog Treat. 2020;31(7):680-686. doi: https://doi.org/10.1080/09546634.2019.1610552Bongartz T, Coras B, Vogt T, Schölmerich J, Müller-Ladner U. Treatment of active psoriatic arthritis with the PPARgamma ligand pioglitazone: an open-label pilot study. Rheumatology (Oxford). 2005;44(1):126-129. doi: https://doi.org/10.1093/rheumatology/keh423Bongartz T, Coras B, Vogt T, Schölmerich J, Müller-Ladner U. Treatment of active psoriatic arthritis with the PPARgamma ligand pioglitazone: an open-label pilot study. Rheumatology (Oxford). 2005;44(1):126-129. doi: https://doi.org/10.1093/rheumatology/keh423Zhao Y, Yang L, Wang X, Zhou Z. The new insights from DPP-4 inhibitors: their potential immune modulatory function in autoimmune diabetes. Diabetes Metab Res Rev. 2014;30(8):646-653. doi: https://doi.org/10.1002/dmrr.2530Zhao Y, Yang L, Wang X, Zhou Z. The new insights from DPP-4 inhibitors: their potential immune modulatory function in autoimmune diabetes. Diabetes Metab Res Rev. 2014;30(8):646-653. doi: https://doi.org/10.1002/dmrr.2530Makdissi A, Ghanim H, Vora M, et al. Sitagliptin exerts an antinflammatory action. J Clin Endocrinol Metab. 2012;97(9):3333-3341. doi: https://doi.org/10.1210/jc.2012-1544Makdissi A, Ghanim H, Vora M, et al. Sitagliptin exerts an antinflammatory action. J Clin Endocrinol Metab. 2012;97(9):3333-3341. doi: https://doi.org/10.1210/jc.2012-1544van Lingen RG, van de Kerkhof PC, Seyger MM, et al. CD26/ dipeptidyl-peptidase IV in psoriatic skin: upregulation and topographical changes. Br J Dermatol. 2008;158(6):1264-1272. doi: https://doi.org/10.1111/j.1365-2133.2008.08515.xvan Lingen RG, van de Kerkhof PC, Seyger MM, et al. CD26/ dipeptidyl-peptidase IV in psoriatic skin: upregulation and topographical changes. Br J Dermatol. 2008;158(6):1264-1272. doi: https://doi.org/10.1111/j.1365-2133.2008.08515.xThielitz A, Reinhold D, Vetter R, et al. Inhibitors of dipeptidyl peptidase IV and aminopeptidase N target major pathogenetic steps in acne initiation. J Invest Dermatol. 2007;127(5):1042-1051. doi: https://doi.org/10.1038/sj.jid.5700439Thielitz A, Reinhold D, Vetter R, et al. Inhibitors of dipeptidyl peptidase IV and aminopeptidase N target major pathogenetic steps in acne initiation. J Invest Dermatol. 2007;127(5):1042-1051. doi: https://doi.org/10.1038/sj.jid.5700439Nishioka T, Shinohara M, Tanimoto N, Kumagai C, Hashimoto K. Sitagliptin, a dipeptidyl peptidase-IV inhibitor, improves psoriasis. Dermatology. 2012;224(1):20-21. doi: https://doi.org/10.1159/000333358Nishioka T, Shinohara M, Tanimoto N, Kumagai C, Hashimoto K. Sitagliptin, a dipeptidyl peptidase-IV inhibitor, improves psoriasis. Dermatology. 2012;224(1):20-21. doi: https://doi.org/10.1159/000333358Nagai H, Fujiwara S, Takahashi Y, Nishigori C. Ameliorating effect of the novel dipeptidyl peptidase-4 inhibitor teneligliptin on psoriasis: A report of two cases. J Dermatol. 2015;42(11):1094-1097. doi: https://doi.org/10.1111/1346-8138.12955Nagai H, Fujiwara S, Takahashi Y, Nishigori C. Ameliorating effect of the novel dipeptidyl peptidase-4 inhibitor teneligliptin on psoriasis: A report of two cases. J Dermatol. 2015;42(11):1094-1097. doi: https://doi.org/10.1111/1346-8138.12955Lynch M, Malara A, Timoney I, et al. Dipeptidyl Peptidase-4 Inhibition in Psoriasis Patients with Diabetes: A Double-Blind Randomized Controlled Trial. Dermatology. 2021;237(1):66-69. doi: https://doi.org/10.1159/000502130Lynch M, Malara A, Timoney I, et al. Dipeptidyl Peptidase-4 Inhibition in Psoriasis Patients with Diabetes: A Double-Blind Randomized Controlled Trial. Dermatology. 2021;237(1):66-69. doi: https://doi.org/10.1159/000502130Mehdi SF, Pusapati S, Anwar MS, et al. Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent. Front Immunol. 2023;14:1148209. doi: https://doi.org/10.3389/fimmu.2023.1148209Mehdi SF, Pusapati S, Anwar MS, et al. Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent. Front Immunol. 2023;14:1148209. doi: https://doi.org/10.3389/fimmu.2023.1148209Насонов Е.Л., Паневин Т.С., Трошина Е.А. Агонисты рецепторов глюкагоноподобного пептида-1: перспективы применения в ревматологии // Научно-практическая ревматология. — 2024. — Т. 62. — №2. — С. 135–144. doi: https://doi.org/10.47360/1995-4484-2024-135-144Nasonov EL, Panevin TS, Troshina EA. Glucagon-like peptide-1 receptor agonists: Prospects for use in rheumatology. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2024;62(2):135–144 (In Russ.) doi: https://doi.org/10.47360/1995-4484-2024-135-144Faurschou A, Pedersen J, Gyldenløve M, et al. Increased expression of glucagon-like peptide-1 receptors in psoriasis plaques. Exp Dermatol. 2013;22(2):150-152. doi: https://doi.org/10.1111/exd.12081Faurschou A, Pedersen J, Gyldenløve M, et al. Increased expression of glucagon-like peptide-1 receptors in psoriasis plaques. Exp Dermatol. 2013;22(2):150-152. doi: https://doi.org/10.1111/exd.12081Buysschaert M, Baeck M, Preumont V, et al. Improvement of psoriasis during glucagon-like peptide-1 analogue therapy in type 2 diabetes is associated with decreasing dermal γδ T-cell number: a prospective case-series study. Br J Dermatol. 2014;171(1):155-161. doi: https://doi.org/10.1111/bjd.12886Buysschaert M, Baeck M, Preumont V, et al. Improvement of psoriasis during glucagon-like peptide-1 analogue therapy in type 2 diabetes is associated with decreasing dermal γδ T-cell number: a prospective case-series study. Br J Dermatol. 2014;171(1):155-161. doi: https://doi.org/10.1111/bjd.12886Ahern T, Tobin AM, Corrigan M, et al. Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study. J Eur Acad Dermatol Venereol. 2013;27(11):1440-1443. doi: https://doi.org/10.1111/j.1468-3083.2012.04609.xAhern T, Tobin AM, Corrigan M, et al. Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study. J Eur Acad Dermatol Venereol. 2013;27(11):1440-1443. doi: https://doi.org/10.1111/j.1468-3083.2012.04609.xChang G, Chen B, Zhang L. Efficacy of GLP-1rA, liraglutide, in plaque psoriasis treatment with type 2 diabetes: a systematic review and meta-analysis of prospective cohort and before-after studies. J Dermatolog Treat. 2022;33(3):1299-1305. doi: https://doi.org/10.1080/09546634.2021.1882658Chang G, Chen B, Zhang L. Efficacy of GLP-1rA, liraglutide, in plaque psoriasis treatment with type 2 diabetes: a systematic review and meta-analysis of prospective cohort and before-after studies. J Dermatolog Treat. 2022;33(3):1299-1305. doi: https://doi.org/10.1080/09546634.2021.1882658Costanzo G, Curatolo S, Busà B, Belfiore A, Gullo D. Two birds one stone: semaglutide is highly effective against severe psoriasis in a type 2 diabetic patient. Endocrinol Diabetes Metab Case Rep. doi: https://doi.org/10.1530/EDM-21-0007Costanzo G, Curatolo S, Busà B, Belfiore A, Gullo D. Two birds one stone: semaglutide is highly effective against severe psoriasis in a type 2 diabetic patient. Endocrinol Diabetes Metab Case Rep. doi: https://doi.org/10.1530/EDM-21-0007Malavazos AE, Meregalli C, Sorrentino F, et al. Semaglutide therapy decreases epicardial fat inflammation and improves psoriasis severity in patients affected by abdominal obesity and type-2 diabetes. Endocrinol Diabetes Metab Case Rep. 2023;2023(3):23-0017. doi: https://doi.org/10.1530/EDM-23-0017Malavazos AE, Meregalli C, Sorrentino F, et al. Semaglutide therapy decreases epicardial fat inflammation and improves psoriasis severity in patients affected by abdominal obesity and type-2 diabetes. Endocrinol Diabetes Metab Case Rep. 2023;2023(3):23-0017. doi: https://doi.org/10.1530/EDM-23-0017Petković-Dabić J, Binić I, Carić B, et al. Effects of Semaglutide Treatment on Psoriatic Lesions in Obese Patients with Type 2 Diabetes Mellitus: An Open-Label, Randomized Clinical Trial. Biomolecules. 2025;15(1):46. doi: https://doi.org/10.3390/biom15010046Petković-Dabić J, Binić I, Carić B, et al. Effects of Semaglutide Treatment on Psoriatic Lesions in Obese Patients with Type 2 Diabetes Mellitus: An Open-Label, Randomized Clinical Trial. Biomolecules. 2025;15(1):46. doi: https://doi.org/10.3390/biom15010046Al Bahadly WKY, Bdioui A, Al-Gazally M, Al-Saedi H, Salah SHB, Ramadhan M. The effect of dapagliflozin ointment on induced psoriasis in an experimental model. J Med Life. 2024;17(3):281-285. doi: https://doi.org/10.25122/jml-2023-0084Al Bahadly WKY, Bdioui A, Al-Gazally M, Al-Saedi H, Salah SHB, Ramadhan M. The effect of dapagliflozin ointment on induced psoriasis in an experimental model. J Med Life. 2024;17(3):281-285. doi: https://doi.org/10.25122/jml-2023-0084Qureshi SA, Finch SE, Pratt ME. A case of probable drug-induced psoriasis to dapagliflozin. SAGE Open Med Case Rep. 2024;12:2050313X241284003. doi: https://doi.org/10.1177/2050313X241284003Qureshi SA, Finch SE, Pratt ME. A case of probable drug-induced psoriasis to dapagliflozin. SAGE Open Med Case Rep. 2024;12:2050313X241284003. doi: https://doi.org/10.1177/2050313X241284003Ma KS, Tsai SY, Holt A, Chen ST. Effects of sodium-glucose cotransporter-2 inhibitors on inflammatory skin diseases in patients with type 2 diabetes. J Am Acad Dermatol. 2024;91(5):934-936. doi: https://doi.org/10.1016/j.jaad.2024.04.079Ma KS, Tsai SY, Holt A, Chen ST. Effects of sodium-glucose cotransporter-2 inhibitors on inflammatory skin diseases in patients with type 2 diabetes. J Am Acad Dermatol. 2024;91(5):934-936. doi: https://doi.org/10.1016/j.jaad.2024.04.079Ma SH, Wu CY, Lyu YS, Chou YJ, Chang YT, Wu CY. Association between sodium-glucose co-transporter 2 inhibitors and risk of psoriasis in patients with diabetes mellitus: a nationwide population-based cohort study. Clin Exp Dermatol. 2022;47(12):2242-2250. doi: https://doi.org/10.1111/ced.15385Ma SH, Wu CY, Lyu YS, Chou YJ, Chang YT, Wu CY. Association between sodium-glucose co-transporter 2 inhibitors and risk of psoriasis in patients with diabetes mellitus: a nationwide population-based cohort study. Clin Exp Dermatol. 2022;47(12):2242-2250. doi: https://doi.org/10.1111/ced.15385Паневин Т.С., Зоткин Е.Г., Трошина Е.А. Аутоиммунный полиэндокринный синдром взрослых. Фокус на ревматологические аспекты проблемы // Терапевтический архив. — 2023. — Т. 95. — №10. — С. 881-887. doi: https://doi.org/10.26442/00403660.2023.10.202484Panevin TS, Zotkin EG, Troshina EA. Autoimmune polyendocrine syndrome in adults. Focus on rheumatological aspects of the problem: A review. Terapevticheskii Arkhiv (Ter. Arkh.). 2023;95(10):881-7 (In Russ.). doi: https://doi.org/10.26442/00403660.2023.10.202484Bowes J, Loehr S, Budu-Aggrey A, et al. PTPN22 is associated with susceptibility to psoriatic arthritis but not psoriasis: evidence for a further PsA-specific risk locus. Ann Rheum Dis. 2015;74(10):1882-1885. doi: https://doi.org/10.1136/annrheumdis-2014-207187Bowes J, Loehr S, Budu-Aggrey A, et al. PTPN22 is associated with susceptibility to psoriatic arthritis but not psoriasis: evidence for a further PsA-specific risk locus. Ann Rheum Dis. 2015;74(10):1882-1885. doi: https://doi.org/10.1136/annrheumdis-2014-207187Bottini N, Vang T, Cucca F, Mustelin T. Role of PTPN22 in type 1 diabetes and other autoimmune diseases. Semin Immunol. 2006;18(4):207-213. doi: https://doi.org/10.1016/j.smim.2006.03.008Bottini N, Vang T, Cucca F, Mustelin T. Role of PTPN22 in type 1 diabetes and other autoimmune diseases. Semin Immunol. 2006;18(4):207-213. doi: https://doi.org/10.1016/j.smim.2006.03.008Ciaffi J, Mele G, Mancarella L, et al. Prevalence of Type 2 and Type 1 Diabetes in Psoriatic Arthritis: An Italian Study. J Clin Rheumatol. 2022;28(2):e324-e329. doi: https://doi.org/10.1097/RHU.0000000000001706Ciaffi J, Mele G, Mancarella L, et al. Prevalence of Type 2 and Type 1 Diabetes in Psoriatic Arthritis: An Italian Study. J Clin Rheumatol. 2022;28(2):e324-e329. doi: https://doi.org/10.1097/RHU.0000000000001706Fatima N, Faisal SM, Zubair S, et al. Role of Pro-Inflammatory Cytokines and Biochemical Markers in the Pathogenesis of Type 1 Diabetes: Correlation with Age and Glycemic Condition in Diabetic Human Subjects. PLoS One. 2016;11(8):e0161548. doi: https://doi.org/10.1371/journal.pone.0161548Fatima N, Faisal SM, Zubair S, et al. Role of Pro-Inflammatory Cytokines and Biochemical Markers in the Pathogenesis of Type 1 Diabetes: Correlation with Age and Glycemic Condition in Diabetic Human Subjects. PLoS One. 2016;11(8):e0161548. doi: https://doi.org/10.1371/journal.pone.0161548Granata M, Skarmoutsou E, Trovato C, Rossi GA, Mazzarino MC, D’Amico F. Obesity, Type 1 Diabetes, and Psoriasis: An Autoimmune Triple Flip. Pathobiology. 2017;84(2):71-79. doi: https://doi.org/10.1159/000447777Granata M, Skarmoutsou E, Trovato C, Rossi GA, Mazzarino MC, D’Amico F. Obesity, Type 1 Diabetes, and Psoriasis: An Autoimmune Triple Flip. Pathobiology. 2017;84(2):71-79. doi: https://doi.org/10.1159/000447777Wilcox NS, Rui J, Hebrok M, Herold KC. Life and death of β cells in Type 1 diabetes: A comprehensive review. J Autoimmun. 2016;71:51-58. doi: https://doi.org/10.1016/j.jaut.2016.02.001Wilcox NS, Rui J, Hebrok M, Herold KC. Life and death of β cells in Type 1 diabetes: A comprehensive review. J Autoimmun. 2016;71:51-58. doi: https://doi.org/10.1016/j.jaut.2016.02.001Honkanen J, Nieminen JK, Gao R, et al. IL-17 immunity in human type 1 diabetes. J Immunol. 2010;185(3):1959-1967. doi: https://doi.org/10.4049/jimmunol.1000788Honkanen J, Nieminen JK, Gao R, et al. IL-17 immunity in human type 1 diabetes. J Immunol. 2010;185(3):1959-1967. doi: https://doi.org/10.4049/jimmunol.1000788Herold KC, Bundy BN, Long SA, et al. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes [published correction appears in N Engl J Med. 2020 Feb 6;382(6):586. doi: https://doi.org/10.1056/NEJMx190033]. N Engl J Med. 2019;381(7):603-613. doi: https://doi.org/10.1056/NEJMoa1902226Herold KC, Bundy BN, Long SA, et al. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes [published correction appears in N Engl J Med. 2020 Feb 6;382(6):586. doi: https://doi.org/10.1056/NEJMx190033]. N Engl J Med. 2019;381(7):603-613. doi: https://doi.org/10.1056/NEJMoa1902226Rigby MR, Harris KM, Pinckney A, et al. Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. J Clin Invest. 2015;125(8):3285-3296. doi: https://doi.org/10.1172/JCI81722Rigby MR, Harris KM, Pinckney A, et al. Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. J Clin Invest. 2015;125(8):3285-3296. doi: https://doi.org/10.1172/JCI81722Gregory JW, Carter K, Cheung WY, et al. Phase II multicentre, double-blind, randomised trial of ustekinumab in adolescents with new-onset type 1 diabetes (USTEK1D): trial protocol. BMJ Open. 2021;11(10):e049595. doi: https://doi.org/10.1136/bmjopen-2021-049595Gregory JW, Carter K, Cheung WY, et al. Phase II multicentre, double-blind, randomised trial of ustekinumab in adolescents with new-onset type 1 diabetes (USTEK1D): trial protocol. BMJ Open. 2021;11(10):e049595. doi: https://doi.org/10.1136/bmjopen-2021-049595Tatovic D, Marwaha A, Taylor P, et al. Ustekinumab for type 1 diabetes in adolescents: a multicenter, double-blind, randomized phase 2 trial. Nat Med. 2024;30(9):2657-2666. doi: https://doi.org/10.1038/s41591-024-03115-2Tatovic D, Marwaha A, Taylor P, et al. Ustekinumab for type 1 diabetes in adolescents: a multicenter, double-blind, randomized phase 2 trial. Nat Med. 2024;30(9):2657-2666. doi: https://doi.org/10.1038/s41591-024-03115-2Marwaha AK, Tan S, Dutz JP. Targeting the IL-17/IFN-γ axis as a potential new clinical therapy for type 1 diabetes. Clin Immunol. 2014;154(1):84-89. doi: https://doi.org/10.1016/j.clim.2014.06.006Marwaha AK, Tan S, Dutz JP. Targeting the IL-17/IFN-γ axis as a potential new clinical therapy for type 1 diabetes. Clin Immunol. 2014;154(1):84-89. doi: https://doi.org/10.1016/j.clim.2014.06.006

The authors declare that there are no conflicts of interest present.